T84 Xenograft Model Service for Colon Cancer

The T84 xenograft model offers a well-differentiated, mucin-secreting platform derived from a human colorectal lung metastasis, making it uniquely suited for studying epithelial barrier integrity and therapeutic response in colon cancer. At Alfa Cytology, we provide a fully customizable T84 xenograft model service for preclinical colon cancer research---backed by rigorous quality control, validated workflows, and expert study design support to accelerate your drug development pipeline.

Overview of T84 Xenograft Model for Colon Cancer

The T84 cell line was originally established from a lung metastasis of a primary colon adenocarcinoma in a 72-year-old male patient. After 23 passages in BALB/c athymic nude mice, the line was established as an adherent epithelial culture that retains tight junctions, desmosomes, and vectorial electrolyte transport. In vivo, T84 xenografts form well-differentiated glandular tumors with prominent luminal spaces, abundant mucin secretion, and preserved epithelial polarity---histological features that closely mimic human colorectal epithelium. The model is particularly valued for its high transepithelial resistance and barrier-forming properties, which are maintained in the xenograft setting and enable studies of tumor progression, barrier dysfunction, and drug permeability in a metastatic-like context.

Molecularly, T84 cells are microsatellite stable (MSS) and harbor wild-type KRAS and BRAF, but carry a mutated TP53 allele. They express low-to-moderate levels of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), and mucin 2 (MUC2), confirming colorectal lineage fidelity. The slow proliferation rate and high differentiation status distinguish T84 from more aggressive colorectal models, making it ideal for evaluating drugs requiring prolonged exposure, assessing mucin-associated drug resistance, and testing EGFR-targeted therapies in a KRAS/BRAF wild-type background. Tumor volumes typically reach 700-900 mm^3 within 5 to 7 weeks, with moderate take rates but stable, reproducible growth kinetics once established.

Figure 1. Expression of Panx1 in T84 cells. (Alhouayek, M, et al., 2019)

Cell Line Information: T84

The following table summarizes the key biological, genetic, and culture characteristics of the T84 cell line, compiled from ATCC, Cellosaurus, and published literature sources.

Our Services

Alfa Cytology is a dedicated preclinical CRO specializing in tumor model services for colon cancer research. Our T84 xenograft platform combines validated cell line authentication, optimized inoculation protocols, and comprehensive endpoint analysis---including tumor growth monitoring, histopathology, immunohistochemistry, and pharmacokinetic/pharmacodynamic assessment---to deliver reproducible, publication-ready data for your therapeutic programs. Whether you are evaluating targeted biologics, small-molecule inhibitors, or combination regimens, our team ensures seamless study execution from protocol design to final report.

Workflow of T84 Xenograft Model Construction

The construction of T84 xenograft tumors follows a standardized, quality-controlled workflow that ensures reproducible tumor growth and reliable pharmacological readouts. Below is a summary of the key stages, from cell preparation to endpoint analysis.

1. Cell Culture and Expansion: T84 cells are maintained in DMEM:F-12 supplemented with 5% fetal bovine serum at 37 degrees C under 5% CO2. Cells are passaged at 1:2 to 1:4 ratios twice weekly, maintaining high density (>25% confluency) to preserve tight junction integrity and epithelial phenotype. Mycoplasma testing and STR authentication are performed prior to inoculation.
2. Cell Harvest and Preparation: Exponentially growing T84 cells are harvested using trypsin-EDTA digestion, washed in sterile PBS, and resuspended at a concentration of 2 x 10^6 to 5 x 10^6 cells per 100-200 microL. For enhanced tumor take, cells may be mixed 1:1 with Matrigel or another basement membrane matrix to support initial engraftment.
3. Animal Preparation and Inoculation: Immunodeficient mice (athymic nude or NOD/SCID, 6-7 weeks old) are acclimatized under specific-pathogen-free (SPF) conditions. T84 cells are injected subcutaneously into the right flank using a sterile syringe. Typical inoculum ranges from 2 x 10^6 to 5 x 10^6 cells per mouse, depending on study design and tumor growth objectives.
4. Tumor Monitoring and Randomization: Tumors are palpated twice weekly and measured with calipers in two perpendicular dimensions. Tumor volume is calculated using the formula V = L x S^2 x 0.52. Once tumors reach approximately 80-100 mm^3, mice are randomized into treatment groups to ensure balanced baseline tumor volumes across cohorts.
5. Treatment Administration and Longitudinal Assessment: Test compounds are administered via the designated route (intraperitoneal, intravenous, or oral gavage) according to the study protocol. Tumor dimensions and body weights are recorded 2-3 times per week. Blood samples may be collected at interim time points for pharmacokinetic analysis.
6. Endpoint Collection and Analysis: At study termination, tumors are excised, weighed, and fixed in formalin for histopathological evaluation. Sections are stained with H&E for morphology assessment, PAS for mucin detection, and immunohistochemistry for CK20, MUC2, claudin-1, ZO-1, and Ki-67. Additional tumor tissue is snap-frozen for molecular analysis or protein extraction.

Figure 2: Schematic workflow illustrating the derivation and construction of the T84 Xenograft Model at Alfa Cytology.

Case Study-T84 Xenograft Model Development

In a recent internal validation study, T84 cells were inoculated subcutaneously into NOD/SCID mice at a density of 5 x 10^6 cells per animal. Tumors became palpable within 14-18 days and exhibited steady, reproducible growth, reaching a mean volume of approximately 750 mm^3 by day 42. Histopathological examination confirmed well-differentiated glandular architecture with prominent mucin pools, strong membranous CK20 and MUC2 staining, and preserved claudin-1 and ZO-1 expression---consistent with the epithelial barrier phenotype observed in vitro. Pharmacodynamic analysis demonstrated measurable target engagement following EGFR inhibitor administration, with dose-dependent reductions in tumor growth rate and downstream signaling marker modulation. These data support the utility of the T84 xenograft model for preclinical efficacy studies in well-differentiated, mucin-producing colon cancer and provide a robust baseline for client-specific therapeutic evaluations. (Detailed client data available upon request.)

Why Choose Alfa Cytology?

Alfa Cytology delivers preclinical tumor model services with a focus on scientific rigor, operational transparency, and client collaboration. Our T84 xenograft program is built on validated protocols and comprehensive quality assurance to ensure data integrity and reproducibility.

• Authenticated cell lines with verified STR profiles and mycoplasma-free certification, ensuring model fidelity and traceability.
• Customizable study designs with flexible dosing schedules, route selection, and endpoint analysis tailored to your therapeutic mechanism.
• Comprehensive histopathology and immunohistochemistry services, including PAS, H&E, and multiplex IHC for barrier proteins, proliferation markers, and lineage confirmation.
• Experienced project management with regular milestone updates, transparent communication, and on-time delivery of interim and final reports.
• Competitive turnaround times and cost-effective pricing without compromising the quality or reproducibility of preclinical data.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated T84 xenograft model? Contact us today to discuss your study objectives, receive a customized protocol, and obtain a competitive project quote. Our team of preclinical specialists is standing by to support your research from initial inquiry to final data delivery. Reach out to us via email or phone, and let Alfa Cytology be your trusted partner in preclinical oncology research.

For research use only. Not intended for any clinical use.